[117Lu]Lu-AKY-807 / Aktis Oncology - LARVOL DELTA

AKTIS ONCOLOGY ANNOUNCES PRESENTATION OF…DATA SUPPORTING BROAD DEVELOPMENT OF A FIRST IN CLASS NECTIN-4 TARGETING RADIOPHARMACEUTICAL AKY-1189 AT 2024 EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS (PRNewswire) - "The first poster (Abstract no. 118), titled, 'Discovery and pre-clinical development of AKY-1189, a potent and selective Nectin-4 miniprotein binder optimized for use as a targeted radiopharmaceutical,' highlighted AKY-1189's preclinical data supporting advancement to clinical development. The second poster (Abstract no. 308), titled, 'Allometric scaling of preclinical dosimetry for the Nectin-4 miniprotein binders AKY-807 and AKY-1189 accurately predicts human absorbed dose to major organs,' highlighted the accuracy of allometric scaling methods in predicting human organ dosimetry from preclinical data."

Preclinical • Oncology